Elevated p53 and p21waf1 mRNA expression in blood lymphocytes from lung cancer patients with chemoresistance

Chuen Ming Shih; Kwunmin Chen; Yu Chieh Wang; Pei Jung Lee; Yi Ching Wang

doi:10.1016/j.cdp.2007.10.003

Elevated p53 and p21waf1 mRNA expression in blood lymphocytes from lung cancer patients with chemoresistance

Chuen Ming Shih, Kwunmin Chen, Yu Chieh Wang, Pei Jung Lee, Yi Ching Wang

Research output: Contribution to journal › Article › peer-review

5 Scopus citations

Abstract

Background: Clinical and experimental studies suggest that alteration of the expression level of the p53 gene and other damage responsive genes may be associated with chemoresistance in cancer patients. Methods: The present study evaluated the differences of the basal levels of lymphocytic p53 and p21waf1 mRNA expression collected before receiving cisplatin-based chemotherapy between 48 chemo-ineffective lung cancer patients and 39 chemo-effective lung cancer patients using an optimized semi-quantitative multiplex reverse transcriptase-polymerase chain reaction (RT-PCR). Results: The data indicated that the mean mRNA level of p53 gene in chemo-ineffective patients (0.66) was 26.9% higher than that of the chemo-effective patients (0.52) with statistical significance (P = 0.03), and a significantly higher level of p21waf1 mRNA expression in the chemo-ineffective patients (P = 0.03) was also observed. In addition, by the multiplex long quantitative PCR analysis, we demonstrated that chemo-ineffective and chemo-effective patients have similar amounts of UV damage on their p53 gene of lymphocyte DNA through equal UV treatment. Conclusion: Our results suggest that elevated levels of p53/p21waf1 mRNA in blood lymphocytes collected before chemotherapy may predict the chemoresponses of lung cancer patients.

Original language	English
Pages (from-to)	366-370
Number of pages	5
Journal	Cancer Detection and Prevention
Volume	31
Issue number	5
DOIs	https://doi.org/10.1016/j.cdp.2007.10.003
State	Published - 2007

Keywords

Chemoresistance
Lung cancer
Lymphocyte
p21waf1 gene
p53 gene

Access to Document

10.1016/j.cdp.2007.10.003

Cite this

@article{ef4cb6d067f9472c87097ff65851cd73,

title = "Elevated p53 and p21waf1 mRNA expression in blood lymphocytes from lung cancer patients with chemoresistance",

abstract = "Background: Clinical and experimental studies suggest that alteration of the expression level of the p53 gene and other damage responsive genes may be associated with chemoresistance in cancer patients. Methods: The present study evaluated the differences of the basal levels of lymphocytic p53 and p21waf1 mRNA expression collected before receiving cisplatin-based chemotherapy between 48 chemo-ineffective lung cancer patients and 39 chemo-effective lung cancer patients using an optimized semi-quantitative multiplex reverse transcriptase-polymerase chain reaction (RT-PCR). Results: The data indicated that the mean mRNA level of p53 gene in chemo-ineffective patients (0.66) was 26.9% higher than that of the chemo-effective patients (0.52) with statistical significance (P = 0.03), and a significantly higher level of p21waf1 mRNA expression in the chemo-ineffective patients (P = 0.03) was also observed. In addition, by the multiplex long quantitative PCR analysis, we demonstrated that chemo-ineffective and chemo-effective patients have similar amounts of UV damage on their p53 gene of lymphocyte DNA through equal UV treatment. Conclusion: Our results suggest that elevated levels of p53/p21waf1 mRNA in blood lymphocytes collected before chemotherapy may predict the chemoresponses of lung cancer patients.",

keywords = "Chemoresistance, Lung cancer, Lymphocyte, p21waf1 gene, p53 gene",

author = "Shih, {Chuen Ming} and Kwunmin Chen and Wang, {Yu Chieh} and Lee, {Pei Jung} and Wang, {Yi Ching}",

note = "Funding Information: Supported in part by Grants NSC94-2320-B-003-002 from the National Science Council and DOH96-TD-G-111-004 from the Department of Health (The Executive Yuan, Republic of China). ",

year = "2007",

doi = "10.1016/j.cdp.2007.10.003",

language = "English",

volume = "31",

pages = "366--370",

journal = "Cancer Detection and Prevention",

issn = "0361-090X",

publisher = "Elsevier BV",

number = "5",

}

TY - JOUR

T1 - Elevated p53 and p21waf1 mRNA expression in blood lymphocytes from lung cancer patients with chemoresistance

AU - Shih, Chuen Ming

AU - Chen, Kwunmin

AU - Wang, Yu Chieh

AU - Lee, Pei Jung

AU - Wang, Yi Ching

N1 - Funding Information: Supported in part by Grants NSC94-2320-B-003-002 from the National Science Council and DOH96-TD-G-111-004 from the Department of Health (The Executive Yuan, Republic of China).

PY - 2007

Y1 - 2007

N2 - Background: Clinical and experimental studies suggest that alteration of the expression level of the p53 gene and other damage responsive genes may be associated with chemoresistance in cancer patients. Methods: The present study evaluated the differences of the basal levels of lymphocytic p53 and p21waf1 mRNA expression collected before receiving cisplatin-based chemotherapy between 48 chemo-ineffective lung cancer patients and 39 chemo-effective lung cancer patients using an optimized semi-quantitative multiplex reverse transcriptase-polymerase chain reaction (RT-PCR). Results: The data indicated that the mean mRNA level of p53 gene in chemo-ineffective patients (0.66) was 26.9% higher than that of the chemo-effective patients (0.52) with statistical significance (P = 0.03), and a significantly higher level of p21waf1 mRNA expression in the chemo-ineffective patients (P = 0.03) was also observed. In addition, by the multiplex long quantitative PCR analysis, we demonstrated that chemo-ineffective and chemo-effective patients have similar amounts of UV damage on their p53 gene of lymphocyte DNA through equal UV treatment. Conclusion: Our results suggest that elevated levels of p53/p21waf1 mRNA in blood lymphocytes collected before chemotherapy may predict the chemoresponses of lung cancer patients.

AB - Background: Clinical and experimental studies suggest that alteration of the expression level of the p53 gene and other damage responsive genes may be associated with chemoresistance in cancer patients. Methods: The present study evaluated the differences of the basal levels of lymphocytic p53 and p21waf1 mRNA expression collected before receiving cisplatin-based chemotherapy between 48 chemo-ineffective lung cancer patients and 39 chemo-effective lung cancer patients using an optimized semi-quantitative multiplex reverse transcriptase-polymerase chain reaction (RT-PCR). Results: The data indicated that the mean mRNA level of p53 gene in chemo-ineffective patients (0.66) was 26.9% higher than that of the chemo-effective patients (0.52) with statistical significance (P = 0.03), and a significantly higher level of p21waf1 mRNA expression in the chemo-ineffective patients (P = 0.03) was also observed. In addition, by the multiplex long quantitative PCR analysis, we demonstrated that chemo-ineffective and chemo-effective patients have similar amounts of UV damage on their p53 gene of lymphocyte DNA through equal UV treatment. Conclusion: Our results suggest that elevated levels of p53/p21waf1 mRNA in blood lymphocytes collected before chemotherapy may predict the chemoresponses of lung cancer patients.

KW - Chemoresistance

KW - Lung cancer

KW - Lymphocyte

KW - p21waf1 gene

KW - p53 gene

UR - http://www.scopus.com/inward/record.url?scp=36549020728&partnerID=8YFLogxK

U2 - 10.1016/j.cdp.2007.10.003

DO - 10.1016/j.cdp.2007.10.003

M3 - Article

C2 - 18035504

AN - SCOPUS:36549020728

SN - 0361-090X

VL - 31

SP - 366

EP - 370

JO - Cancer Detection and Prevention

JF - Cancer Detection and Prevention

IS - 5

ER -

Elevated p53 and p21waf1 mRNA expression in blood lymphocytes from lung cancer patients with chemoresistance

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this